文献速递心脑血管急症重症综合管理与镇静镇痛

卵圆孔未闭封堵术与抗血小板治疗对隐源性卒中的疗效比较

Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
PubMed 文献 · N Engl J Med · 2017-01-01
一句话结论隐源性卒中合并卵圆孔未闭患者,封堵术联合抗血小板治疗较单用抗血小板治疗降低复发性缺血性卒中风险(HR 0.23),但封堵术组房颤和器械相关不良事件更多。

这项多国随机试验纳入664例隐源性卒中合并卵圆孔未闭患者,按2:1随机分配至卵圆孔未闭封堵术联合抗血小板治疗组或单用抗血小板治疗组。中位随访3.2年,封堵术组临床缺血性卒中复发率1.4%(6/441),单用抗血小板组5.4%(12/223),风险比0.23(95%CI 0.09-0.62,P=0.002)。封堵术组新发脑梗死发生率5.7%低于单用抗血小板组11.3%(相对风险0.51,95%CI 0.29-0.91,P=0.04),但无症状脑梗死发生率两组无显著差异(P=0.97)。封堵术组器械相关严重不良事件6例(1.4%),封堵术后房颤29例(6.6%),作者认为封堵术与器械并发症及房颤发生率升高相关。

要点

  • 隐源性卒中合并卵圆孔未闭患者,封堵术联合抗血小板治疗较单用抗血小板治疗降低复发性临床缺血性卒中风险(1.4% vs 5.4%,HR 0.23,95%CI 0.09-0.62,P=0.002)。
  • 封堵术组新发脑梗死(临床缺血性卒中或影像学无症状脑梗死复合终点)发生率5.7%,低于单用抗血小板组的11.3%(RR 0.51,95%CI 0.29-0.91,P=0.04)。
  • 两组无症状脑梗死发生率无显著差异(P=0.97)。
  • 封堵术组严重不良事件23.1%,单用抗血小板组27.8%(P=0.22),无显著差异;封堵术组器械相关严重不良事件6例(1.4%),封堵术后发生房颤29例(6.6%)。
  • 纳入患者平均年龄45.2岁,81%存在中度或大型心房水平分流。

适用人群与场景

  • 隐源性卒中合并卵圆孔未闭患者,平均年龄45.2岁,81%存在中度或大型心房水平分流。
  • 多国随机试验纳入664例,按2:1随机分配至封堵术联合抗血小板治疗组(441例)或单用抗血小板治疗组(223例)。

处置流程与药物剂量

  • 卵圆孔未闭封堵术联合抗血小板治疗组:行卵圆孔未闭封堵术并接受抗血小板治疗。
  • 单用抗血小板治疗组:仅接受抗血小板治疗,未行封堵术。
  • 基线筛查及24个月时行脑影像学检查。

研究设计与关键结果

  • 多国随机试验,纳入664例隐源性卒中合并卵圆孔未闭患者,按2:1随机分配至封堵术联合抗血小板治疗组(441例)或单用抗血小板治疗组(223例),中位随访3.2年。
  • 主要终点之一为随机化后至少24个月内无临床缺血性卒中证据:封堵术组复发6/441(1.4%),单用抗血小板组复发12/223(5.4%),HR 0.23(95%CI 0.09-0.62,P=0.002)。
  • 另一主要终点为24个月新发脑梗死(临床缺血性卒中或影像学检出的无症状脑梗死复合终点):封堵术组22例(5.7%),单用抗血小板组20例(11.3%),RR 0.51(95%CI 0.29-0.91,P=0.04)。
  • 无症状脑梗死发生率两组无显著差异(P=0.97)。
  • 严重不良事件:封堵术组23.1%,单用抗血小板组27.8%(P=0.22),无显著差异。
  • 封堵术组器械相关严重不良事件6例(1.4%),封堵术后发生房颤29例(6.6%)。

证据类型、等级与局限

  • 多国随机对照试验(Gore REDUCE,ClinicalTrials.gov NCT00738894),由W.L. Gore and Associates资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,隐源性卒中合并卵圆孔未闭患者中,封堵术联合抗血小板治疗者后续缺血性卒中风险低于单用抗血小板治疗者,但封堵术与器械并发症及房颤发生率升高相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO closure combined with antiplatelet therapy versus antiplatelet therapy alone on the risks of recurrent stroke and new brain infarctions.

METHODS: In this multinational trial involving patients with a PFO who had had a cryptogenic stroke, we randomly assigned patients, in a 2:1 ratio, to undergo PFO closure plus antiplatelet therapy (PFO closure group) or to receive antiplatelet therapy alone (antiplatelet-only group). Imaging of the brain was performed at the baseline screening and at 24 months. The coprimary end points were freedom from clinical evidence of ischemic stroke (reported here as the percentage of patients who had a recurrence of stroke) through at least 24 months after randomization and the 24-month incidence of new brain infarction, which was a composite of clinical ischemic stroke or silent brain infarction detected on imaging.

RESULTS: We enrolled 664 patients (mean age, 45.2 years), of whom 81% had moderate or large interatrial shunts. During a median follow-up of 3.2 years, clinical ischemic stroke occurred in 6 of 441 patients (1.4%) in the PFO closure group and in 12 of 223 patients (5.4%) in the antiplatelet-only group (hazard ratio, 0.23; 95% confidence interval [CI], 0.09 to 0.62; P=0.002). The incidence of new brain infarctions was significantly lower in the PFO closure group than in the antiplatelet-only group (22 patients [5.7%] vs. 20 patients [11.3%]; relative risk, 0.51; 95% CI, 0.29 to 0.91; P=0.04), but the incidence of silent brain infarction did not differ significantly between the study groups (P=0.97). Serious adverse events occurred in 23.1% of the patients in the PFO closure group and in 27.8% of the patients in the antiplatelet-only group (P=0.22). Serious device-related adverse events occurred in 6 patients (1.4%) in the PFO closure group, and atrial fibrillation occurred in 29 patients (6.6%) after PFO closure.

CONCLUSIONS: Among patients with a PFO who had had a cryptogenic stroke, the risk of subsequent ischemic stroke was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone; however, PFO closure was associated with higher rates of device complications and atrial fibrillation. (Funded by W.L. Gore and Associates; Gore REDUCE ClinicalTrials.gov number, NCT00738894 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017. PMID: 28902580. doi:10.1056/NEJMoa1707404

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。